Dong Kim - 31 Jan 2024 Form 4/A Insider Report for UroGen Pharma Ltd. (URGN)

Role
Chief Financial Officer
Signature
/s/ Jason D. Smith, Attorney-in-Fact
Issuer symbol
URGN
Transactions as of
31 Jan 2024
Net transactions value
$0
Form type
4/A
Filing time
12 Feb 2024, 17:47:51 UTC
Date Of Original Report
02 Feb 2024
Previous filing
08 Sep 2023
Next filing
12 Sep 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction URGN Ordinary Shares Options Exercise +3,333 +10% 35,253 31 Jan 2024 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer.
F2 This amendment corrects and restates the Amount of Securities Beneficially Owned Following Reported Transaction reported in the original Form 4 filed on February 2, 2024.